Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies

By sjmartinez • November 26, 2024

Chin KM, Channick R, Kim NH, Ong R, Turricchia S, Martin N, Mitchell L, McLaughlin VV. Macitentan in Pulmonary Arterial Hypertension Due to Congenital Heart Disease (CHD-PAH): Real-World Evidence from the OPUS/OrPHeUS Studies. Cardiol Ther. 2024 Nov 25. doi: 10.1007/s40119-024-00386-1. Epub ahead of print. PMID: 39585521.

Tags: congenital heart disease, Macitentan, Publications, pulmonary arterial hypertension, Pulmonary, Critical Care & Sleep Medicine, real-world evidence

Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests

Soo Hoo GW, Chang MR, Sather CC. Comparing Changes in FDG-PET Activity in Sarcoidosis to Changes in Pulmonary Function Tests. Arch Bronconeumol. 2024 Dec 5:S0300-2896(24)00452-6.[...]

CPX-351 plus gemtuzumab ozogamicin for relapsed/refractory acute myelogenous leukemia: a University of California Hematologic Malignancies Consortium trial

Oliai C, Park S, Damon LE, Jonas BA, Jeyakumar D, Wieduwilt MJ, Logan AC, Callas B, Hannigan CA, Gaut DL, Schiller GJ. CPX-351 plus gemtuzumab[...]

Decreases in hemoglobin and hematocrit may signal degree of hemorrhagic shock: retrospective evaluation in a dog model

Jahr JS, Dang J, Tong A, Iskandar S, Patel A, Grogan T, Hopster K, Driessen B, Gunther RA. Decreases in hemoglobin and hematocrit may signal[...]